Table 4 Results of the outcome measures for the organophosphate spray session (OP) and the placebo spray session (PL)
Variable | OP (n = 42) | PL (n = 42) | P value* | ||
|---|---|---|---|---|---|
Baseline | Follow up | Baseline | Follow up | ||
PchE activity (U/mL) | |||||
Mean (SD) | 1.58 (0.41) | 1.60 (0.40) | 1.58 (0.42) | 1.60 (0.41) | 0.775a |
Symptoms | |||||
Sum of all symptoms | 42 | 41 | 31 | 40 | 0.378b |
Number of symptoms per farmer, n (%) | |||||
0 | 22 (52.4) | 23 (54.8) | 27 (64.3) | 21 (50.0) | |
1 | 11 (26.2) | 10 (23.8) | 6 (14.3) | 10 (23.8) | |
2 | 5 (11.9) | 3 (7.1) | 6 (14.3) | 5 (11.9) | |
≥ 3 | 4 (9.5) | 6 (14.3) | 3 (7.1) | 6 (14.3) | |
Distribution, n (%) | |||||
Headache | 6 (14.3) | 10 (23.8) | 4 (9.5) | 10 (23.8) | |
Dizziness | 1 (2.4) | 1 (2.4) | 2 (4.8) | 6 (14.3) | |
Skin irritation | 7 (16.7) | 9 (21.4) | 3 (7.1) | 10 (23.8) | |
Extreme tiredness | 4 (9.5) | 5 (11.9) | 6 (14.3) | 5 (11.9) | |
Weakness | 6 (14.3) | 3 (7.1) | 4 (9.5) | 2 (4.8) | |
Anxiety | 3 (7.1) | 1 (2.4) | 0 (0.0) | 1 (2.4) | |
Excessive sweating | 5 (11.9) | 4 (9.5) | 1 (2.4) | 0 (0.0) | |
Trembling hands | 1 (2.4) | 1 (2.4) | 1 (2.4) | 1 (2.4) | |
Vomiting | 0 (0.0) | 0 (0.0) | 1 (2.4) | 0 (0.0) | |
Diarrhea | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Abdominal pain | 1 (2.4) | 2 (4.8) | 1 (2.4) | 1 (2.4) | |
Blurred vision | 4 (9.5) | 1 (2.4) | 3 (7.1) | 4 (9.5) | |
Paralysis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Salivation | 1 (2.4) | 1 (2.4) | 1 (2.4) | 0 (0.0) | |
Tearing | 0 (0.0) | 0 (0.0) | 2 (4.8) | 0 (0.0) | |
Lack of coordination | 0 (0.0) | 1 (2.4) | 0 (0.0) | 0 (0.0) | |
Respiratory difficulties | 3 (7.1) | 2 (4.8) | 2 (4.8) | 0 (0.0) | |
Confusion | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |